Paion AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PAIOF research report →
Companywww.paion.com
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.
- CEO
- Gregor Siebert
- IPO
- 2009
- Employees
- 64
- HQ
- Aachen, DE
Price Chart
Valuation
- Market Cap
- $75.26K
- P/E
- -4.44
- P/S
- 0.08
- P/B
- 0.39
- EV/EBITDA
- 3.46
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 94.10%
- Op Margin
- 4.53%
- Net Margin
- -1.74%
- ROE
- -8.51%
- ROIC
- 5.58%
Growth & Income
- Revenue
- $33.25M · 366.44%
- Net Income
- $-579,000 · 97.34%
- EPS
- $-0.08 · 97.39%
- Op Income
- $1.50M
- FCF YoY
- 110.78%
Performance & Tape
- 52W High
- $0.05
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 4.08
- Avg Volume
- 15.60K
Get TickerSpark's AI analysis on PAIOF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our PAIOF Coverage
We haven't published any research on PAIOF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PAIOF Report →